CALiBRe: Assessment of the Mechanism of Action of idelalisib (CAL101) in B-cell Receptor Pathway Inhibition in CLL

Trial Profile

CALiBRe: Assessment of the Mechanism of Action of idelalisib (CAL101) in B-cell Receptor Pathway Inhibition in CLL

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Dec 2017

At a glance

  • Drugs Idelalisib (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Pharmacodynamics
  • Acronyms CALiBRe
  • Most Recent Events

    • 26 Dec 2017 The recruitment was temporarily halted in April 2016 due to the idelalisib safety alert from other trials, according to presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
    • 12 Dec 2017 Results (n=23) assessing idelalisib in patients with chronic lymphocytic leukaemia, were presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
    • 31 May 2017 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top